Application | Comment | Organism |
---|---|---|
pharmacology | CatK is an established drug target for osteoporosis | Mus musculus |
Protein Variants | Comment | Organism |
---|---|---|
additional information | bone marrow transplantation for selective disruption of CatK in the haematopoietic system, usage of total bone marrow progenitor cells from CatK-/-, CatK-/+, and CatK+/+, and low-density lipoprotein receptor knockout mice. Silencing of leucocyte CatK results in phenotypic changes in bone formation with an increased total bone mineral density in the CatK2/2 chimeras, effect of leucocyte cathepsin K deficiency on bone remodelling, overview | Mus musculus |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | Mus musculus | absence of leucocyte CatK results in dramatically decreased collagen and increased macrophage content of the atherosclerotic lesions while lesion size is not affected | ? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
bone | - |
Mus musculus | - |
leukocyte | - |
Mus musculus | - |
additional information | CatK is upregulated in atherosclerotic lesions | Mus musculus | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | absence of leucocyte CatK results in dramatically decreased collagen and increased macrophage content of the atherosclerotic lesions while lesion size is not affected | Mus musculus | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
catK | - |
Mus musculus |